Raymond James Financial
TLX

Raymond James Financial’s Telix Pharmaceuticals TLX Stock Holding History

Raymond James Financial’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,200
Closed -$19.3K – 6957
2025
Q2 		$19.3K Buy
+1,200
New +$20.1K ﹤0.01% 5612

Other funds holding TLX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

Raymond James Financial's TLX Position: Q3 2025 in Review

Raymond James Financial sold out of Telix Pharmaceuticals (TLX) in Q3 2025, closing a stake of 1,200 shares — an estimated $19.3K sold.

Raymond James Financial first reported a position in TLX in Q2 2025 and held it in 1 quarter. The position peaked at $19.3K in Q2 2025. 27 funds tracked by Wall St. Rank hold TLX as of Q3 2025.

  • Raymond James Financial reported no remaining Telix Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 1,200 Telix Pharmaceuticals shares in Q3 2025, an estimated $19.3K.
  • Raymond James Financial first reported a position in Telix Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Telix Pharmaceuticals position peaked at $19.3K in Q2 2025.
  • 27 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.